Read more

December 06, 2023
1 min read
Save

Top in endocrinology: Discrimination in drug trials; quality of life in transgender youth

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Five obesity advocacy groups are calling on the FDA to require drug trials to include people with obesity and to update labels for drugs that may affect people with obesity differently.

“We must ensure drugs are safe and effective and labeled correctly for everyone for whom they are intended,” Angela Fitch, MD, FACP, FOMA, Dipl. ABOM, president of the Obesity Medicine Association, associate director of the Massachusetts General Hospital Weight Center and an instructor of medicine at Harvard Medical School, said in a joint statement.

Various Colored Pills
Five obesity advocacy groups are calling on the FDA to require drug trials to include people with obesity and to update labels for drugs that may affect people with obesity differently. Image Source: Adobe Stock

It was the top story in endocrinology last week.

The second top story was about a study that found transgender and gender-expansive young people reported having a lower quality of life compared with the general public.

Read these and more top stories in endocrinology below:

Joint statement calls for FDA to require drug trials to include people with obesity

Five obesity advocacy organization have issued a joint statement asking the FDA to mandate that all drug approval trials include people with obesity. Read more.

Transgender young people report worse mental health than general population

Transgender and gender-expansive young people report worse quality of life mental health scores compared with the general U.S. population, according to study data. Read more.

Glycemia Risk Index bests time in range in assessing hypoglycemia for adults with diabetes

The new continuous glucose monitoring metric Glycemia Risk Index better assesses hypoglycemia risk than time in range, according to study data. Read more.

Greater use of CGM linked to glycemic benefits for pregnant women with type 2 diabetes

Pregnant women with type 2 diabetes who used continuous glucose monitoring only had improvements in CGM metrics if they used the device more than 50% of the time, according to data published in Diabetes Technology & Therapeutics. Read more.

Walking faster may reduce risk for developing type 2 diabetes

Walking at a faster speed may decrease the risk for developing type 2 diabetes, though more studies are needed to confirm the association, according to findings from a systematic review and meta-analysis. Read more.